Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Editas Medicine Inc (NASDAQ: EDIT) closed at $2.28 in the last session, up 7.55% from day before closing price of $2.12. In other words, the price has increased by $7.55 from its previous closing price. On the day, 5.46 million shares were traded. EDIT stock price reached its highest trading level at $2.33 during the session, while it also had its lowest trading level at $2.13.
Ratios:
We take a closer look at EDIT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.08 and its Current Ratio is at 3.08. In the meantime, Its Debt-to-Equity ratio is 0.50 whereas as Long-Term Debt/Eq ratio is at 0.29.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 03 ’25 when Parison Amy sold 446 shares for $1.72 per share. The transaction valued at 769 led to the insider holds 17,506 shares of the business.
Burkly Linda sold 726 shares of EDIT for $1,252 on Jun 03 ’25. The EVP, CHIEF SCIENTIFIC OFFICER now owns 69,519 shares after completing the transaction at $1.72 per share. On Jun 03 ’25, another insider, O’Neill Gilmore Neil, who serves as the CEO of the company, sold 15,192 shares for $1.72 each. As a result, the insider received 26,196 and left with 280,282 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 190865408 and an Enterprise Value of 1034318. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.33 while its Price-to-Book (P/B) ratio in mrq is 3.06. Its current Enterprise Value per Revenue stands at 0.029 whereas that against EBITDA is -0.005.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.13, which has changed by -0.50542295 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $6.05, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is 31.69%, while the 200-Day Moving Average is calculated to be 12.31%.
Shares Statistics:
According to the various share statistics, EDIT traded on average about 2.13M shares per day over the past 3-months and 3284700 shares per day over the past 10 days. A total of 83.71M shares are outstanding, with a floating share count of 82.95M. Insiders hold about 0.91% of the company’s shares, while institutions hold 54.29% stake in the company. Shares short for EDIT as of 1749772800 were 8426415 with a Short Ratio of 3.96, compared to 1747267200 on 9091921. Therefore, it implies a Short% of Shares Outstanding of 8426415 and a Short% of Float of 10.09.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Editas Medicine Inc (EDIT) is the result of assessments by 10.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.33, with high estimates of -$0.21 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.58 and -$2.13 for the fiscal current year, implying an average EPS of -$1.88. EPS for the following year is -$1.14, with 13.0 analysts recommending between -$0.75 and -$1.78.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $24.08M, while the lowest revenue estimate was $4.7M, resulting in an average revenue estimate of $13.01M. In the same quarter a year ago, actual revenue was $32.31M
